Loading...
•
Jun 30, 2022
Generation Bio Q2 2022 Earnings Report
Generation Bio's financial results and business highlights were reported for Q2 2022.
Key Takeaways
Generation Bio reported a net loss of $37.9 million for the second quarter of 2022. The company's cash, cash equivalents, and marketable securities totaled $312.2 million as of June 30, 2022, expected to fund operations into 2025.
Advanced non-viral genetic medicine platform for durable, redosable non-viral DNA therapeutics.
Process development and scaling of rapid enzymatic synthesis (RES) enabled a more flexible and capital-efficient manufacturing strategy.
Announced update to Good Manufacturing Practice (GMP) manufacturing strategy.
Dannielle Appelhans was appointed to the Board of Directors.
Generation Bio
Generation Bio
Forward Guidance
Any statements in this press release about future expectations, plans and prospects for the company, including statements about the company’s strategic plans or objectives, manufacturing plans, cash resources, technology platform, including RES, research and clinical development plans, and preclinical data and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.